Candida, still number one - What do we know and where are we going from there?

Mycoses, Supplement

Volumn 48, Issue 1, 2005, Pages 3-11

  Segal, Esther ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Candida; Diagnosis; Epidemiology; Etiology; Therapy; Virulence

Indexed keywords

ALLYLAMINE; AMPHOCYL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CLOTRIMAZOLE; FLUCYTOSINE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; TERBINAFINE;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONFERENCE PAPER; CONTROLLED STUDY; HOST PATHOGEN INTERACTION; HUMAN; INCIDENCE; INFECTION; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIDE EFFECT; SKIN INFECTION; THRUSH; VAGINITIS;

AGED; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CELL LINE; CHILD; CHILD, PRESCHOOL; FEMALE; FUNGEMIA; HUMANS; MICE; VIRULENCE;

EID: 17844368617     PISSN: 09437312     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. de Hoog GS, Guarro J, Gené J, Figueras MJ. Ascomycetous yeasts: Genus: Candida. In: Atlas of Clinical Fungi, 2nd edn. Utrecht, The Netherlands: Centraalbureau voor Schimmelcultures, 2000: 180-226.
2. Meyer SA, Payne RW, Yarrow D. Candida Berkhout. In: Kurtzman CP, Fell JW (eds), The Yeasts, A Taxonomic Study 4th edn. Amsterdam: Elsevier, 1998: 454-573.
3. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-60.
4. Pfaller MA, Jones RN, Doern GV et al. Blood stream infections due to Candida species: SENTRY antimicrobial surveillance in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44: 747-51.
5. Sanglard D, Bille A. Current understanding of modes of action and resistance mechanisms to conventional and emerging antifungal agents for treatment of Candida infections. In: Calderone RA (eds), Candida and Candidiasis. Washington DC: ASM Press, 2002: 349-83.
6. Krcmery V, Huttova M. Mateika F et al. Breakthrough fungemia in neonates and infants caused by Candida albicans and Candida parapsilosis susceptible to fluconazole in vitro. J Antimicrob Chemoth 2001; 48: 521-5.
7. Rangel-Frausto M, Wiblin T, Blumberg HM et al National epidemiology of mycoses (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infec Dis 1999; 29: 253-8.
8. Girmenia C, Martino P, De Bernardis F et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors and differential pathogenicity of the causative strains. Clin Infect Dis 1996; 23: 506-14.
9. Krcmery V, Kovacicova G. Longitudinal 10-year prospective survey of fungemia in Slovak Republic: Trends in etiology in 310 episodes. Diagn Microbiol Infect Dis 2000; 36: 7-11.
10. Pagano L. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes, Eur J Haematol 1999; 63: 77-85.
11. Douglas JL. Candida biofilms and their role in infection. Trends in Microbiol 2003; 11: 30-36.
12. Al-Fattani MA, Douglas JL. Penetration of Candida biofilms by antifungal agents. Antimicrob Agents Chemother 2004; 48: 3291-7.
13. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov., phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiol 1995; 14: 1507-21.
14. Gutierrez J, Morales P, Gonzales MA, Quindos G. Candida dubliniensis, a new fungal pathogen. J Basic Microbiol 2002; 42: 207-27.
15. Hasenclever HF, Mitchell WO. Antigenic studies of Candida. I. Observations of two antigenic groups in Candida albicans. J Bacteriol 1961; 82: 570-3.
16. Slutsky B, Buffo J, Soil DR. High frequency switching of colony morphology in Candida albicans. Science 1985; 23: 666-9.
17. Enger L, Joly S, Pujol C, Simson P, Pfaller M, Soil DR. Cloning and characterization of a complex DNA finger-printing probe for Candida parapsilosis. J Clin Microbiol 2001; 39: 658-69.
18. Hull CM, Johnson AD. Identification of a mating type-like locus in the asexual pathogenic yeast Candida albicans. Science 1999; 285: 1271-5.
19. Magee BB, Magee PT. Induction of mating in Candida albicans by construction of MTLa and MTL alpha strains. Science 2000; 28: 310-3.
20. Riggsby WS, Torres-Bauza LJ, Wills JW, Townes TM. DNA content, kinetic complexity and ploidity question in Candida albicans. Mol Cell Biol 1982; 2: 853-62.
21. Chibana H, Beckerman JL, Magee PT. Fine-resolution physical mapping of genomic diversity in Candida albicans. Genome Res 2000; 1: 1865-77.
22. Sullivan D. Rationale for sequencing the Candida dubliniensis genome, Candida and Candidiasis. ASM Conference, 2004.
23. Edwards JE. Candida species. In: Mandell GL, Bennett JE, Dolin R (eds), Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone, 2000: 2656-74.
24. Pfaller MA. Nosocomial fungal infections: a look at emerging pathogens and threats to the future. Focus on Fungal Infections, 2003.
25. Navarro-Garcia F, Sanchez M, Nombela C, Pla J. Virulence genes in the pathogenic yeast Candida albicans. FEMS Microbiol Rev 2001; 25: 245-68.
26. Haynes K. Virulence in Candida species. Trends Microbiol 2001; 9: 591-6.
27. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance, J Bacteriol 2001; 83: 5385-94.
28. Hube B, Naglik J. Candida albicans proteinases: resolving the mystery of a gene family. Microbiology 2001; 147: 1997-2005.
29. Sanglard D, Hube B, Monod M, Odds FC, Gow NA. A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of Candida albicans causes attenuated virulence. Infect Immun 1997; 6: 3539-46.
30. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis, Clin Microbiol Rev 2000; 1: 122-43.
31. Segal E, Virulence factors. In: E Segal, Baum GL (eds), Pathogenic Yeasts and Yeast Infections. Boca Raton: CRC Press, 1994: 49-60.
32. Segal E, SandovskyLosica H, Interaction of Candida with mammalian tissues in vitro and in vivo. In: Doyle RJ, Ofek I (eds), Methods of Enzymology. San Diego: Academic Press, Adhesion of Microbial Pathogen 1995; 253: 439-52.
33. Segal E., SandovskyLosica H, Basis for Candida albicans adhesion and penetration. In: Jacobs PH, Nall L (eds), Fungal Disease. New York: Marcel Dekker, 1997.
34. Calderone RA., Braun P. Adherence and receptor relationship of Candida albicans. Microbiol Rev 1991; 55: 1-20.
35. Segal E. Inhibitors of Candida albicans adhesion to prevent candidiasis. In: Segal E (eds), Toward anti-adhesion therapy for microbial diseases. New York: Plenum Press, 1996: 197-206.
36. Hoyer LL. The ALS gene family of Candida albicans. Trends Microbiol 2001; 9: 176-80.
37. Hosteller MK. RGD mediated adhesion in fungal pathogens of humans, plants and insects. Curr Opin Micobiol 2000; 3: 344-8.
38. Tsarfaty I, Sandovsky-Losica H, Mittelman L, Berdicevsky I, Segal E. Cellular actin is affected by interaction with Candida albicans. FEMS Microbiol Lett 2000; 189: 225-32.
39. Sandovsky-Losica H, Berdicevsky I, Tsarfaty I, Segal E. Effect of Candida albicans metabolites on cellular actin. FEMS Microbiol Lett 2002; 215: 57-62.
40. Romani L. Immunology of invasive candidiasis. In: Calderone RA (eds), Candida and Candidiasis. Washington DC: ASM Press, 2002: 223-42.
41. Romani L, Bistoni F. Systemic immunity in candidiasis. In: Calderone RA, Cihlar RL (eds), Fungal Pathogenesis: Principles and Clinical Applications. New York: Marcel Dekker, 2002: 483-514.
42. De Bernardis F, Boccanera M, Adriani D, Girolamo A, Cassone A. Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect Immun 2002; 70: 2725-9.
43. Mencacci A, Cenci E, Bistoni F, et al. Specific and non-specific immunity to Candida albicans; a lesson from genetically modified animals. Res Immunol 1998; 149: 352-61.
44. Cutler J, Granger BL, Han Y, Vaccines, antibodies and passive immunity in candidiasis. In: Calderone RA, Cihlar RL (eds), Fungal Pathogenesis: Principles and Clinical Applications. New York: Marcel Dekker, 2002: 325-52.
45. Segal E. Vaccines against fungal infections. Crit Rev Microbiol 1987; 14: 229-71.
46. Segal E, Elad D, Immunizations against fungal diseases in man and animals. In: Arora DK (eds), Handbook of Fungal Biotechnology. New York: Marcel Dekker, 2004: 503-14.
47. Matthews R, Burnie J. Antifungal antibodies: a new approach to the treatment of systemic candidiasis. Curr Opin Investig Drugs 2001; 2: 472-6.
48. Cutler J, Granger BL, Han Y. Immunoprotection against candidiasis. In: Calderone RA (eds), Candida and Candidiasis. Washington DC: ASM Press, 2002: 243-56.
49. Matthews R, Hodgetts S, Burnie J. Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. J Infect Dis 1995; 171: 1668-71.
50. Merz WG, Roberts GD. Algorithms for detection and identification of fungi. In: Murray PR, Baron EJ, Pfaller MA, et al. (eds), Manual of Clinical Microbiology, 7th edn. Washington DC: ASM Press, 1999: 1167-83.
51. Reiss E, Kaufman L, Kovacs JA, Lindsley MD. Clinical Immunomycology. In: Rose NR, Hamilton RG, Detrick B (eds), Manual of Clinical Laboratory Immunology, 6th edn. Washington DC: ASM Press, 2002: 559-83.
52. Richardson M, Carlson P. Culture and non-culture based diagnostics of Candida species. In: Calderone RA, Cihlar RL (eds), Fungal Pathogenesis: Principles and Clinical Applications. New York: Marcel Dekker, 2002: 387-94.
53. Odds FC, Brown AJP, Gow NA. Antifungal agents: mechanism of action. Trends Microbiol 2003; 11: 272-9.
54. Shadkhan Y, Segal E. Antifungal activity of amphotericin B-intralipid admixtures in experimental candidosis in naïve mice. J Ant Chem 1999; 44: 787-90.
55. Shadkhan Y, Segal E. Treatment of experimental candidosis with amphotericin B-intralipid admixtures in immunocompromised mice. J Ant Chem 2001; 48: 245-51.
56. Choi EH. Genetics and susceptibility to infections: a primer for clinicians. Focus On Fungal Infections, 2003.
57. Sandovsky-Losica H, Chauhan N, Calderone RA. Segal E. Actin rearrangement in HEp2 cell occurs during infection with Candida albicans. Candida and Candidiasis. ASM Conference, 2004.